VSTM vs. MACK, VNDA, RIGL, XOMA, RGLS, EBS, LXRX, OPK, INVA, and PBYI
Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Merrimack Pharmaceuticals (MACK), Vanda Pharmaceuticals (VNDA), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Regulus Therapeutics (RGLS), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), Innoviva (INVA), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical preparations" industry.
Merrimack Pharmaceuticals (NASDAQ:MACK) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.
Merrimack Pharmaceuticals has higher earnings, but lower revenue than Verastem. Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Verastem received 194 more outperform votes than Merrimack Pharmaceuticals when rated by MarketBeat users. However, 67.00% of users gave Merrimack Pharmaceuticals an outperform vote while only 65.20% of users gave Verastem an outperform vote.
In the previous week, Verastem had 2 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 3 mentions for Verastem and 1 mentions for Merrimack Pharmaceuticals. Verastem's average media sentiment score of 0.30 beat Merrimack Pharmaceuticals' score of -0.32 indicating that Merrimack Pharmaceuticals is being referred to more favorably in the media.
Merrimack Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.
64.0% of Merrimack Pharmaceuticals shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 28.9% of Merrimack Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Verastem's return on equity of -6.24% beat Merrimack Pharmaceuticals' return on equity.
Verastem has a consensus price target of $28.79, indicating a potential upside of 206.88%. Given Merrimack Pharmaceuticals' higher possible upside, analysts clearly believe Verastem is more favorable than Merrimack Pharmaceuticals.
Summary
Merrimack Pharmaceuticals beats Verastem on 8 of the 15 factors compared between the two stocks.
Get Verastem News Delivered to You Automatically
Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verastem Competitors List
Related Companies and Tools
